RxDoctor Payments Data

Ryan Bozzell

Nurse Practitioner · Farmington, NMNPI 1447722657

Payments from drug & device makers

$340in general payments, 2019–2025

Across 18 payments — averaging $18.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$74
  • AbbVie$73
  • Dexcom, Inc.$50
  • Lilly USA, LLC$40
  • Pfizer$32
  • Alkermes, Inc.$29
  • plus $42 from 3 others

What the payments were for

  • Food & beverage$340100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck4$74
AbbVie3$73
Dexcom, Inc.3$50
Lilly USA, LLC2$40
Pfizer2$32
Alkermes, Inc.1$29
Medtronic1$15
GSK1$15
AstraZeneca1$13

How this compares

$340 in reported general payments places this provider in the 75th percentile of 624 nurse practitioner providers in New Mexico.

See all nurse practitioner providers in New Mexico

Medicare billing

Part B allowed, 2024
$33,124
Medicare patients
142
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban71$71,205
TrulicityDulaglutide32$42,307
OzempicSemaglutide37$32,709
JardianceEmpagliflozin14$19,224
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog12$15,924
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$13,943
LinzessLinaclotide24$13,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$3,561
Atorvastatin Calcium218$3,281
Humalog Kwikpen U-100Insulin Lispro15$2,655
Venlafaxine Hcl ErVenlafaxine Hcl38$2,475
Albuterol Sulfate HfaAlbuterol Sulfate79$2,402
Lidocaine15$2,223
Lisinopril205$2,130
Gabapentin142$1,947

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$32$71,20571 claims
Lilly USA, LLCTrulicity$40$42,30732 claims
AbbVieLinzess$73$13,80424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 624 nurse practitioner providers in New Mexico.

Other nurse practitioner in Farmington

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →